|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-5-20
|
|
pubmed:abstractText |
The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. AREAS COVERED BY THIS REVIEW: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which focused on Emerging Raf Inhibitors published in this same review series.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1744-7623
|
|
pubmed:author |
pubmed-author:AbramsSteven LSL,
pubmed-author:BonatiAntonioA,
pubmed-author:CervelloMelchiorreM,
pubmed-author:ChappellWilliam HWH,
pubmed-author:LibraMassimoM,
pubmed-author:LunghiPaoloP,
pubmed-author:MartelliAlberto MAM,
pubmed-author:McCubreyJames AJA,
pubmed-author:MilellaMicheleM,
pubmed-author:MontaltoGiuseppeG,
pubmed-author:NicolettiFerdinandoF,
pubmed-author:OveRogerR,
pubmed-author:RussoSuzanneS,
pubmed-author:SteelmanLinda SLS,
pubmed-author:StivalaFrancaF,
pubmed-author:TafuriAgostinoA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
203-23
|
|
pubmed:meshHeading |
pubmed-meshheading:20151845-Animals,
pubmed-meshheading:20151845-Antineoplastic Agents,
pubmed-meshheading:20151845-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20151845-Apoptosis,
pubmed-meshheading:20151845-Cell Proliferation,
pubmed-meshheading:20151845-Chemotherapy, Adjuvant,
pubmed-meshheading:20151845-Drugs, Investigational,
pubmed-meshheading:20151845-Enzyme Activation,
pubmed-meshheading:20151845-Humans,
pubmed-meshheading:20151845-MAP Kinase Kinase Kinases,
pubmed-meshheading:20151845-Neoplasms,
pubmed-meshheading:20151845-Protein Kinase Inhibitors,
pubmed-meshheading:20151845-Radiotherapy, Adjuvant,
pubmed-meshheading:20151845-Signal Transduction,
pubmed-meshheading:20151845-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Emerging MEK inhibitors.
|
|
pubmed:affiliation |
Brody School of Medicine at East Carolina University, Department of Microbiology & Immunology, 600 Moye Boulevard, Greenville, NC 27858, USA. mccubreyj@ecu.edu
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
